Cook Medical Makes Zilver PTX Drug-Eluting Stent Available in Canada

June 5, 2014—Cook Medical announced the launch of the Zilver PTX paclitaxel-eluting peripheral stent in Canada at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Quebec, Canada. The Zilver PTX is indicated for use in treating new or recurring lesions as long as 140 mm per leg. In Canada, Zilver PTX is sold in lengths of 40, 60, 80, and 100 mm and in diameters of 6 and 7 mm. The self-expanding Zilver PTX is the first drug-coated stent in Canada indicated to treat peripheral arterial disease in the superficial femoral artery (SFA), noted the company.

According to Cook Medical, long-term data from the international Zilver PTX randomized trial show 75% of patients treated with the drug-eluting Zilver PTX maintained blood flow in the SFA at 4 years. By contrast, there was 57.9% patency for patients who received a bare-metal Zilver stent at 4 years. Gary Ansel, MD, presented the 4-year data from the Zilver PTX randomized controlled trial in October at the VIVA 2013: Vascular Interventional Advances conference in Las Vegas, Nevada.

In the United States, the Cook Zilver PTX paclitaxel-eluting peripheral stent received US Food and Drug Administration approval in November 2012. The device was first launched in 2009 in Europe and is now available in more than 50 countries across Europe, the Middle East, North and South America, and the Asia-Pacific region.